NASDAQ: LTRN - Lantern Pharma Inc.

Lønnsomhet i seks måneder: -22.27%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Lantern Pharma Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

flere detaljer
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 10.03
Prisendring per dag: -2.84% (3.52)
Prisendring per uke: +8.74% (3.145)
Prisendring per måned: +9.97% (3.11)
Prisendring over 3 måneder: -9.4% (3.775)
Prisendring over seks måneder: -22.27% (4.4)
Prisendring per år: -20.09% (4.28)
Prisendring over 3 år: -53.41% (7.34)
Prisendring over 5 år: 0% (3.42)
Prisendring over 10 år: 0% (3.42)
Prisendring siden begynnelsen av året: +11.04% (3.08)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
Total: 3.63

Effektivitet

Navn Betydning Karakter
ROA, % -36.57 0
ROE, % -39.02 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0132 10
Total: 7.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 557.78 10
Lønnsomhet EPS, % 276.99 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.00743 17.09 1.54048
Dimensional U.S. Targeted Value ETF 0.00011 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098



Veileder Stillingstittel Betaling Fødselsår
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 år)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 år)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 år)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

Adresse: United States, Dallas. TX, 1920 McKinney Avenue - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.lanternpharma.com